• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

aMoon II Raises $600M Digital Health Fund to Invest in Mid to Late-Stage Companies

by Fred Pennic 01/11/2019 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

aMoon II

Israeli-based health tech and life sciences venture fund aMoon II has raised $600 million from investors and aims to raise up to $750 million by its close in February, Reuters reported. The fund’s objective is to generate strong investment returns by partnering with promising mid-late-stage companies in Israel and in select other global centers of healthtech innovation.

aMoon II Investment Focus

Founded in 2018,  aMoon II secured a $250 million investment commitment from Credit Suisse’s asset management and private banking divisions. The $600 million is up from the original target of $500 million for the venture fund and will focus on investing in mid to late-stage companies in biopharma, medical device, and digital health companies in Israel, the United States, and Europe. 

The fund intends to invest $10 million to $40 million in 15 to 20 companies over the next five years. In addition, the aMoon has launched a third fund, aMoon Velocity will focus on early-stage highly disruptive healthcare technologies, open exclusively to aMoon II investors. 

The fund is founded by Dr. Yair Schindel, its managing partner, and Marius Nacht, the billionaire co-founder of cybersecurity giant CheckPoint Software Technologies. Nacht is investing $360 million of his own money in the three funds. 

Portfolio Companies

aMoon II has invested in four companies to date, including cancer therapy firm Ayala Pharmaceuticals ($10.6M), antibody (Ab) drug development company Biolojic Design, medical device company CartiHeal; and radiology imaging analytics platform Zebra Medical Vision. 

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: aMoon, Israeli digital health startups

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Interview

Reach7 Diabetes Studios Founder Chun Yong on Reimagining Chronic Care with a Concierge Medical Model

Most-Read

Particle Health Addresses Integration to Epic Data Despite Dispute

US Court Allows Particle’s Antitrust Claims Against Epic to Proceed

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Preparing for the ‘Big Beautiful Bill’: How Digitization Can Streamline Medicaid Eligibility & Social Care Delivery

Preparing for the ‘Big Beautiful Bill’: How Digitization Can Streamline Medicaid Eligibility & Social Care Delivery

Evernorth Health Services Invests $3.5B in Shields Health Solutions

Evernorth Health Services Invests $3.5B in Shields Health Solutions

KLAS Report: Oracle Health Faces Customer Losses and Declining Satisfaction

KLAS Report: Oracle Health Faces Customer Losses and Declining Satisfaction

Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

M&A:Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

Mira Launches Ultra4™, the First At-Home Hormone Monitor with Lab-Quality Insights

Femtech: Mira Launches Ultra4™, the First At-Home Hormone Monitor with Lab-Quality Insights

How Healthcare CIOs Can Solve the Unstructured Data Crisis and Reduce Storage Costs

How Healthcare CIOs Can Solve the Unstructured Data Crisis and Reduce Storage Costs

Healthcare C-Suite Acknowledges AI Potential but Lacks Trust

Sage Growth Partners Report: Healthcare C-Suite Acknowledges AI Potential but Lacks Trust

EVERSANA and Waltz Health Merge to Redefine Pharmaceutical Commercialization

EVERSANA and Waltz Health Merge to Redefine Pharmaceutical Commercialization

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |